Arcus Biosciences Inc (RCUS)
15.56
+0.06
(+0.39%)
USD |
NYSE |
Nov 04, 16:00
15.55
-0.01
(-0.06%)
After-Hours: 20:00
Arcus Biosciences Profit Margin (Quarterly): -238.5% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -238.5% |
| March 31, 2024 | -2.76% |
| December 31, 2023 | -261.3% |
| September 30, 2023 | -221.9% |
| June 30, 2023 | -258.6% |
| March 31, 2023 | -320.0% |
| December 31, 2022 | -197.1% |
| September 30, 2022 | -197.0% |
| June 30, 2022 | -248.1% |
| March 31, 2022 | -377.8% |
| December 31, 2021 | 78.83% |
| September 30, 2021 | -824.2% |
| June 30, 2021 | -803.0% |
| March 31, 2021 | -767.3% |
| Date | Value |
|---|---|
| December 31, 2020 | -521.5% |
| September 30, 2020 | 2.82% |
| June 30, 2020 | -2.58K% |
| March 31, 2020 | -1.59K% |
| December 31, 2019 | -170.2% |
| September 30, 2019 | -1.28K% |
| June 30, 2019 | -1.61K% |
| March 31, 2019 | -1.01K% |
| December 31, 2018 | -787.1% |
| September 30, 2018 | -252.0% |
| June 30, 2018 | -1.08K% |
| March 31, 2018 | -1.04K% |
| December 31, 2017 | -1.06K% |
| September 30, 2017 | -14.19K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-2.58K%
Minimum
Jun 2020
78.83%
Maximum
Dec 2021
-499.4%
Average
-258.6%
Median
Jun 2023
Profit Margin (Quarterly) Benchmarks
| Merck & Co Inc | 18.95% |
| Intra-Cellular Therapies Inc | -15.03% |
| Syndax Pharmaceuticals Inc | -1.94K% |
| Clearside Biomedical Inc | -8.44K% |
| Janux Therapeutics Inc | -66.98% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -43.08% |
| Return on Assets | -20.80% |
| Return on Invested Capital | -43.08% |
| Operating Margin (Quarterly) | -271.8% |
| Return on Net Operating Assets | -274.2% |